To investigate the potential impact of select tumor molecular alterations on the immune profiles of tumors treated with neoadjuvant therapy, we analyzed the immune scores in resected tumors by EGFR mutations/ALK rearrangements, KRAS mutations and TP53 alterations as compared to wild-type tumors. This evidence concerns the gene KRAS and neoplasm.